Article
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Blood advances - 27 Feb 2018
Stone Richard M, Manley Paul W, Larson Richard A, Capdeville Renaud
Abstract excerpt
Midostaurin was a prototype kinase inhibitor, originally developed as a protein kinase C inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor. Despite promising preclinical data, early clinical trials in multiple diseases...
Topics
- Drug Approval
- Drug Discovery
- History, 20th Century
- History, 21st Century
- Humans
- Leukemia, Myeloid, Acute
- Mastocytosis, Systemic
- Mutation
- Proto-Oncogene Mas
- Staurosporine
- United States
- United States Food and Drug Administration
- fms-Like Tyrosine Kinase 3